Want to create an interactive transcript for this episode?
Podcast: OncLive® On Air
Episode: FDA Approval Insights: Taletrectinib in ROS1+ Advanced/Metastatic NSCLC: With Joel Neal, MD, PhD; and Christian Rolfo, MD, PhD
Description: In today’s episode, supported by Nuvation Bio, we spoke with Joel Neal, MD, PhD, and Christian Rolfo, MD, PhD, about the FDA approval of taletrectinib (Ibtrozi) for the treatment of patients with locally advanced or metastatic, ROS1-positive non–small cell lung cancer (NSCLC). Dr Neal is a professor of medicine in the Division of Oncology at the Stanford Cancer Institute at Stanford University in Palo Alto, California. Dr Rolfo is the director of the Division of Medical Oncology at The Ohio State University Comprehensive Cancer Center—James and a professor in the College of Medicine at The Ohio State...